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Background: Small, nonrandomized clinical trials have demonstrated a beneficial
effect of solutions containing insulin and glucose on the recovery of myocardial
metabolism and ventricular function after cardioplegic arrest and reperfusion. How-
ever, no large, blinded, randomized study has yet determined the effects of insulin-
enhanced cardioplegia on clinical outcomes after coronary artery bypass grafting.
Methods: The Insulin Cardioplegia Trial was designed to evaluate the clinical
impact of insulin-enhanced cardioplegia on patients at high risk undergoing isolated
coronary artery bypass grafting for unstable angina. A total of 1127 patients were
randomly assigned at operation to receive cardioplegic solution supplemented with
10 IU/L insulin (n  557) or placebo (n  570). All personnel with direct patient
contact were blinded to randomization group.
Results: Overall operative mortality was 2.2%, with no significant differences
between groups. The prevalences of postoperative low output syndrome (insulin
10.4%, placebo 9.7%, P  .7) and enzymatic myocardial infarction (insulin 21.0%,
placebo 18.8%, P  .3) were not different between groups. The primary composite
outcome of low output syndrome and/or enzymatic myocardial infarction revealed
no difference between groups (insulin 30.0%, placebo 26.3%, P  .2).
Conclusions: Despite encouraging results from smaller, nonrandomized studies, the
Insulin Cardioplegia Trial failed to demonstrate a clinical benefit of insulin-
enhanced cardioplegic solution for patients undergoing high-risk isolated coronary
artery bypass grafting.
Several reports from large database registries have documented theimproved clinical results after isolated coronary artery bypass grafting(CABG).1,2 However, certain groups of patients continue to faceincreased risk of morbidity and mortality after this operation. Theseinclude patients with left ventricular dysfunction, elderly patients, andpatients who undergo urgent operations because of unstable angina or
critical coronary anatomy.3-5
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in these high-risk populations. Demonstration of incremen-
tal benefits for conventional clinical outcomes such as mor-
tality and Q-wave myocardial infarction (MI), however,
would require prohibitively high numbers of patients to
achieve clinical and statistical significance. We have previ-
ously demonstrated that postoperative low cardiac output
syndrome (LOS) is an alternative objective outcome that
may be used to evaluate alternate methods of myocardial
protection.6 In addition, determining the area under the
curve of creatine kinase MB isoenzyme fraction (CKMB)
over time provides a more sensitive measure of enzymatic
myocardial injury.7,8 In the Warm Heart Trial,7 the largest
prospective evaluation of myocardial protection to date, the
incidence of postoperative LOS and enzymatic MI was
more than 20% among patients undergoing urgent opera-
tions. Any clinical evaluation of a new cardioplegic inter-
vention should therefore be targeted toward the reduction of
LOS and enzymatic MI in those patients with unstable
angina who require urgent, isolated CABG.
In 1965, Sodi-Pollares and colleagues9 first described the
beneficial effects of a glucose-insulin-potassium infusion on
the electrocardiographic changes during acute MI. The use
of glucose-insulin solutions during heart operations has
produced conflicting results.10,11 One potential confounding
factor in the early studies of glucose-insulin-potassium so-
lutions was the routine use of moderately hypothermic
(25°C-28°C) cardiopulmonary bypass. In retrospect, meta-
bolic stimulation of the heart may not have been effective at
temperatures that inhibit normal enzyme function. The ad-
vent of normothermic or warm heart surgery has prompted
a renewed interest in myocardial protection.7 We believe
that a reassessment of myocardial metabolic stimulation is
required at systemic and myocardial temperatures that more
closely reflect current standards of practice and in patients
who may receive the most potential benefit. The Insulin
Cardioplegia Trial was designed as a large, double-blinded,
prospective randomized trial to evaluate the impact of in-
sulin-enhanced cardioplegia on objective clinical outcomes
after isolated, urgent CABG for unstable angina or critical
coronary anatomy.
Methods
Patient Population
A total of 3301 patients underwent urgent isolated CABG at
Toronto General Hospital (n  2382) or Sunnybrook and Wom-
en’s College Health Science Centre (n  919) between June 1996
and July 1999. There were 1271 patients screened for possible
entry into this study, 1127 (34%) of whom were eventually ran-
domly assigned to receive either insulin-enhanced cardioplegic
solution (n  557) or placebo (n  570). Exclusion criteria for the
study included any potential for concomitant surgery (eg, left
ventricular aneursymectomy or mitral valve repair), failure to
obtain consent, refusal to participate, or inclusion in a competing
clinical trial. A demographic comparison between study partici-
pants and nonparticipants has demonstrated no differences in post-
operative LOS or perioperative MI.
The requirement for urgent surgery at the University of Toronto
is determined by a combination of symptoms and coronary anat-
omy. Patients with angina refractory to intravenous medical ther-
apy or those with critical left main coronary artery stenosis are
recommended to undergo surgery within 72 hours of cardiac
catheterization on an urgent basis. All patients enrolled in the study
signed a written consent form approved by the respective institu-
tion’s investigational review board.
Surgical Technique
A computer-generated randomization schedule was created and
stratified by institution and surgeon to allow participants to con-
duct the surgical procedure according to individual preference. All
patients received uniform perioperative anesthetic care, which has
been described in detail previously elsewhere.12,13 Before anes-
thetic induction, a perfusionist not involved in the study case
would open a sealed randomization envelope and proceed to
prepare the study cardioplegic solution. Patients randomly as-
signed to the insulin group received a final concentration of 10
IU/L of Humulin R (Eli Lilly Canada; Mississauga, Ontario,
Canada), whereas the placebo group received an equal volume of
the inactive vehicle solution (courtesy of Eli Lilly Canada). All
personnel with direct patient contact both during and after surgery
remained blinded to the randomization group. The final cardiople-
gic solution has been described previously and represented an 8:1
mixture of oxygenated blood to crystalloid solution to achieve the
following final concentrations: 6 mEq/L magnesium sulfate, 50
mmol/L glucose, and either a low (8 mEq/L) or a high (30 mEq/L)
concentration of potassium chloride.14 All patients received an
initial infusion of the high-potassium solution followed by main-
tenance with the low-potassium formulation.
Surgeons were permitted to use antegrade delivery of car-
dioplegic solution, retrograde delivery, or a combination of ante-
grade and retrograde delivery. Similarly, the cardioplegic temper-
ature and the degree of systemic hypothermia were left up to
surgeon preference. All proximal and distal anastomoses were
completed during a single crossclamp period in most cases. Mea-
surements of arterial blood gases, hematocrit, serum glucose, and
serum potassium were performed every 20 minutes during the
crossclamp period. Treatment of perioperative hypoglycemia or
hyperglycemia is described in detail here and was standardized, as
was the treatment of hyperkalemia.
Treatment of Hypoglycemia, Hyperglycemia, and
Hyperkalemia
A strict protocol was developed for the treatment of abnormal
serum glucose levels because of possible neurologic concerns
related to hyperglycemia or hypoglycemia. Normal values in our
laboratory range from 3 to 7 mmol/L. Because of the increased
concern about hypoglycemia versus hyperglycemia, patients were
given intravenous dextrose (25-g boluses) for any blood sugar
value less than 5 mmol/L in the first four hours after the operation.
In a pilot study, we observed that those patients with a blood sugar
less than 10 mmol/L before leaving the operating room were at risk
for development of hypoglycemia in the early postoperative peri-
od.14 Patients were therefore given a 25-g intravenous bolus of
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dextrose if their last intraoperative blood sugar was less than 10
mmol/L. Because of the neurologic concerns of severe hypergly-
cemia, all patients with a blood sugar greater than 20 mmol/L in
the first 4 postoperative hours were given a 5- to 10-IU intravenous
bolus of Humulin R. In cases of insulin-dependent diabetes or
persistent hyperglycemia, an intravenous insulin drip was admin-
istered until the patient reverted to the usual preoperative insulin
regimen.
Patients with hyperkalemia during the crossclamp period were
treated with furosemide or intravenous insulin. If the serum po-
tassium level rose above 5.5 mmol/L, a 20-mg intravenous bolus
of furosemide was administered. If the serum potassium climbed
above 6.0 mmol/L, a 10-IU bolus of insulin was given intrave-
nously.
Study Outcomes
The composite primary end point of the trial was the development
of enzymatic MI, postoperative LOS, or both. Enzymatic MI was
determined after obtaining serial measurements of CKMB. Mea-
surements of CKMB were performed at 0, 2, 4, 8, 24, and 48 hours
after arrival into the intensive care unit. Integration of the CKMB
release over time curve was performed in all patients with at least
4 samples (n  962, 85%). An integrated value greater than 1000
IU  h was used as a binary cutoff for the determination of
enzymatic MI.8 To account for survivors with fewer than 4 sam-
ples, an analysis was repeated with two different end points for
enzymatic MI: peak CKMB greater than 20 and peak CKMB/
creatine kinase ratio greater than 5%.
Clinical records of all patients who received intra-aortic bal-
loon pump or postoperative inotropic support were flagged and
reviewed by an independent outcomes committee blinded to treat-
ment group. Each record was reviewed by at least three individuals
(see Appendix 1 for outcomes committee members), and a deter-
mination of LOS was made by majority opinion.
All other clinical outcomes were recorded by the respective
institution’s clinical database manager. Stroke was defined as any
new gross neurologic deficit or abnormal computed tomographic
scan result. A description of the primary study end points is
provided in Appendix 2.
Statistical Analysis
All data were collected prospectively and entered into a trial
database. The SAS statistical software package (version 6.0 for
Windows; SAS Institute, Inc, Cary, NC) was used for all statistical
analyses. Categorical variables were analyzed with the 2 test or
Fisher exact test as appropriate and are expressed as absolute or
percentage frequencies. Continuous data were analyzed with the
Student t test and are expressed as mean  SD. Stepwise logistic
regression analyses were performed to determine the independent
predictors of LOS, MI, and the primary composite endpoint. Exact
probability values are reported to enable the reader to discern
clinical and statistical significance.
Results
Patient Demographic Characteristics
Table 1 compares the preoperative demographic character-
istics in the insulin and placebo groups. Despite the ran-
domized nature of the trial, patients in the insulin group
were more likely to have depressed ventricular function
(P .02) and left main coronary artery stenosis (P .001).
In addition, patients in the insulin group were more likely to
have symptoms of congestive heart failure (P  .001).
Intraoperative Data
Table 2 compares the intraoperative data between the two
groups. There were no significant differences in any of the
operative variables apart from total cardioplegic volume.
Patients in the insulin group received more cardioplegia
than did those in the placebo group, although the difference
is probably not clinically significant. The total volume of
crystalloid delivered in the insulin group translates into a
mean insulin dose of 44 IU per patient given directly to the
heart during a mean crossclamp period of 66 minutes.
Exogenous Insulin and Glucose Treatment
Figure 1 compares the needs for exogenous insulin or glu-
cose between the groups. According to protocol, insulin was
given intravenously to treat severe hyperglycemia or hyper-
kalemia in 190 patients (32%) in the placebo group and 70
(12%) in the insulin group (P  .001). Patients who re-
quired insulin received a mean intravenous dose of 17  14
IU in the insulin group and 16 12 IU in the placebo group
(P  .5). Intravenous administration of dextrose was re-
quired to treat hypoglycemia in 32 patients (5%) in the
insulin group and 19 patients (3%) in the placebo group
(P  .05). No patient with perioperative hypoglycemia had
any neurologic complications. Among patients who re-
quired exogenous dextrose therapy, a mean dose of 36 
45 g was administered in the insulin group, compared with
22  9 g in the placebo group (P  .09).
Primary End Points
The prevalences of the primary and secondary end-points in
each group are displayed in Figure 2. There were no differ-
ences in either LOS, enzymatic MI, or the composite end
point of LOS and/or MI. The mean area under the CKMB
time curve in the insulin group was 972  759 IU  h (range
246-9352 IU  h) and in the placebo group was 883 IU  h
(range 122-14,039 IU  h, P  .5). Separate analyses for the
alternate definitions of enzymatic MI revealed no group
differences (data not shown).
Subgroup and Multivariable Analyses
Because of baseline differences in demographic character-
istics between groups, both subgroup and multivariable
analyses were performed. Figure 3 demonstrates the effect
of preoperative disposition (coronary care unit vs regular
floor), left ventricular function, and congestive heart failure
on the prevalence of LOS with or without MI in each of the
groups. Patients proceeding to surgery from the coronary
care unit had a higher prevalence of LOS, MI, or both than
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did those housed on the regular floor (37% vs 28%, P 
.01). There was no effect of either left ventricular function
or congestive heart failure, nor were there any significant
differences between groups after stratification for each of
these risk factors. Figure 4 demonstrates the effect of car-
dioplegic temperature on the primary outcome. Again, there
were no differences between groups at any cardioplegic
temperature. Similarly, cardioplegic direction did not affect
the development of LOS or enzymatic MI.
A stepwise logistic regression model was developed for
the primary outcome of LOS and/or MI. Reoperation (odds
ratio 3.92, 95% confidence interval 2.06-7.46), preoperative
status (cardiac care unit vs floor odds ratio 1.44, 95%
confidence interval 1.05-1.98), and age (odds ratio 1.02,
95% confidence interval 1.00-1.03) were the independent
predictors of LOS and/or MI.
Discussion
Despite the well-documented improvements in surgical out-
comes after CABG, certain subgroups continue to be at high
risk for perioperative morbidity and mortality.1-6 Improve-
ments in myocardial protection may improve the results of
surgery in these high-risk subgroups, but documentation of
a clinically significant effect has become increasingly dif-
ficult. The current mortality rate associated with isolated
CABG (2%) necessitates the recruitment of thousands of
patients to demonstrate even a 50% reduction in death. We
have previously shown that postoperative LOS is a more
sensitive measure of ischemic injury that correlates with
mortality, MI, and other objective clinical outcomes.6 The
Insulin Cardioplegia Trial was therefore designed to pro-
spectively evaluate the ability of preischemic metabolic
enhancement to improve the results of surgery in high-risk
TABLE 1. Preoperative patient characteristics in the Insulin Cardioplegia Trial
Insulin (n  557) Placebo (n  570) P value
Age (y, mean  SD) 64 11 63 10 .5
Body surface area (m2, mean  SD) 2.0 0.2 2.0 0.2 .8
Female gender 26% 26% .9
New York Heart Association functional class .2
I 1% 0%
II 2% 3%
III 8% 6%
IV 89% 91%
Preoperative disposition .3
Floor 81% 78%
Coronary care unit 19% 22%
Congestive heart failure 13% 6% .001
Previous surgery 4% 4% .9
Diabetes mellitus .8
Type 1 22% 21%
Type 2 7% 6%
Hypertension 58% 57% .9
Peripheral vascular disease 17% 13% .09
Chronic obstructive pulmonary disease 2% 2% .9
Hypercholesterolemia 65% 66% .9
Renal insufficiency 5% 4% .3
Preoperative MI .2
Unspecified 8% 7%
Non-Q wave 19% 15%
Q wave 10% 8%
Left ventricular ejection fraction .02
60% 31% 33%
40%-59% 42% 49%
20%-39% 24% 16%
20% 3% 2%
Extent of coronary artery disease .6
Single vessel 26% 25%
Double vessel 16% 17%
Triple vessel 58% 58%
Left main coronary artery disease
10% 35% 26% .001
50% 10% 7% .04
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patients undergoing urgent, isolated CABG for unstable
angina.
Previous, smaller studies have documented metabolic,
functional and clinical benefits of glucose-insulin-contain-
ing solutions. Lazar and colleagues15,16 completed two pro-
spective randomized trials in patients with diabetes and in
Figure 1. Requirement for exogenous insulin to treat hyperkale-
mia or hyperglycemia was higher in placebo group (white bars).
Requirement for intravenous glucose to treat hypoglycemia was
higher in insulin cardioplegia group (black bars). Asterisk indi-
cates P < .05; double asterisk indicates P < .001.
Figure 2. Prevalences of LOS, enzymatic MI, and primary com-
posite end point of LOS and/or MI (LOS/MI) in the Insulin Cardio-
plegia Trial. There were no statistically significant differences in
any objective clinical outcomes between placebo group (white
bars) and insulin cardioplegia group (black bars).
TABLE 2. Perioperative patient characteristics in the Insulin Cardioplegia Trial
Insulin (n  557) Placebo (n  570) P value
Cardiopulmonary bypass time (min, mean  SD) 83 27 82 24 .3
Crossclamp time (min, mean  SD) 66 21 64 20 .3
No. of grafts .8
1 1% 1%
2 9% 11%
3 33% 32%
4 41% 41%
5 14% 14%
6 1% 1%
Conduit used
Left internal thoracic artery 93% 95% .3
Right internal thoracic artery 4% 3% .2
Cardioplegic temperature .9
Warm (32°C) 10% 9%
Tepid (25°C-32°C) 37% 39%
Cold (10°C) 53% 51%
Cardioplegic direction .7
Antegrade 68% 69%
Retrograde 7% 5%
Antegrade and retrograde 24% 25%
Cardioplegic volume (L) 4.4 5.0 4.0 2.7 .04
Inotropic support
Renal dose dopamine 24% 24% .6
Norepinephrine for low systemic vascular resistance 7% 5% .5
High dose 10% 10% .7
Intra-aortic balloon pump 5.0% 3.9% .3
LOS 10% 10% .7
MI 21% 19% .3
Postoperative stroke 2.7% 2.7% .3
Ventilation (h, mean  SD) 18 51 11 7 .1
Hospital stay (d, mean  SD) 12 13 11 6 .2
Operative mortality 2.1% 2.2% .4
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patients undergoing urgent surgery for unstable angina. In
contrast to our results, they reported improvements in clin-
ical outcomes, including a reduction in postoperative atrial
fibrillation and shorter ventilation, intensive care unit stay,
and hospital stay. Unfortunately, these studies were not
blinded and only included a small number of patients (n 
30). Another important distinction is the use of intravenous
insulin therapy for 24 hours after the operation. In the
Insulin Cardioplegia Trial, insulin was given only in the
cardioplegic solution and was not continued into the post-
operative period. Our previous blinded study of patients
undergoing elective CABG demonstrated a metabolic and
functional benefit of insulin cardioplegia that lasted for 4
hours after crossclamp removal.14 It is therefore conceivable
that a combination approach in which insulin cardioplegia is
supplemented with postoperative intravenous therapy might
afford substantial clinical benefit.
There were several controversial details in the design of
this trial. First, contamination with insulin in the placebo
group may have confounded the overall results. Almost a
third of the patients in the placebo group received insulin to
treat hyperglycemia or hyperkalemia. Extrapolation of the
data of Lazar and coworkers implicates this contamination
as a possible cause for the relatively low rate of LOS in the
placebo group. We repeated our analysis and eliminated the
190 patients in the placebo group who received intravenous
insulin, but we still failed to demonstrate any beneficial
effect of insulin therapy. In the Warm Heart Trial,7 normo-
thermic cardioplegia resulted in a 33% reduction in the
incidence of LOS, from 9% to 6% (P  .05). Despite
restriction of the trial to high-risk patients with unstable
angina, the overall LOS rate of 10% in the Insulin Cardio-
plegia Trial approached that of the Warm Heart Trial. The
combined rate of LOS and/or MI in the Warm Heart Trial
was 20%, compared with 28% in Insulin Cardioplegia Trial,
which is reflective of the higher risk patient population. The
study was sufficiently powered to detect a 50% reduction in
LOS (94% power) and a 25% reduction in either enzymatic
MI (82% power) or the composite primary outcome (89%
power).
Table 1 illustrates that roughly 30% of patients in both
groups received postoperative inotropic support. However,
only 5% of patients required intra-aortic balloon pump
support, and the total rate of LOS (as determined by com-
mittee) was only 10%. Thus two thirds of the patients who
received inotropic support received either low-dose dopa-
mine for renal perfusion or transient levophed for low
systemic vascular resistance in the setting of high cardiac
output.
Another possible confounding effect was related to the
differences in cardioplegic technique among the participat-
ing surgeons. We deliberately stratified the study by sur-
geon to assess the effect of insulin enhancement in a wide
Figure 3. Subgroup analysis for Insulin Cardioplegia Trial. Prev-
alence of primary composite end point (LOS and/or MI) is shown
in each cardioplegic group. Patients proceeding to surgery from
intensive care unit (ICU) had higher rate of primary composite end
point than did those housed on regular floor (37% vs 28%, P .01).
There was no effect of either left ventricular ejection fraction
(LVEF) or congestive heart failure (CHF) on rate of LOS and/or MI.
There were no differences between groups when stratified for
preoperative status (intensive care unit vs floor), left ventricular
function (left ventricular ejection fraction <40% or >40%), or
presence of congestive heart failure.
Figure 4. Prevalences of LOS, MI, and primary composite end
point (LOS, MI, or both, LOS/MI), are shown for each cardioplegic
study group and temperature range. There were no differences
between groups even when stratified by cardioplegic tempera-
ture. Incidence of enzymatic MI was lower in placebo group in
those patients who received cold cardioplegia. Asterisk indi-
cates P < .05.
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variety of cardioplegic strategies. We believe that this de-
cision improved the generalizability of this study to all
cardiac surgeons, irrespective of their individual cardiople-
gic technique. A subgroup analysis failed to demonstrate
any effect of either cardioplegic temperature or direction on
the development of LOS, although the prevalence of enzy-
matic MI was higher among the patients who received
normothermic blood cardioplegia. In an analysis by car-
dioplegic temperature or direction, there was no group ef-
fect on the prevalence of the primary composite outcome.
Finally, the use of alternate end points might have demon-
strated differences between groups. The study of Lazar and
colleagues15 used an inotrope score that revealed a reduc-
tion in inotropic support in those patients who received
intravenous insulin.
Summary of Study Limitations
The following are limitations of the study: high use of
intravenous insulin in the placebo group, short-term (intra-
operative) administration of study drug, variability in car-
dioplegic temperature and delivery, and relatively low rate
of adverse events. The evaluation of metabolic enhance-
ment before anticipated ischemia required reexamination in
the contemporary era of blood cardioplegia and relative
normothermia. This prospective, randomized, double-blind
trial failed to demonstrate any meaningful clinical benefit to
those patients who received insulin-enhanced cardioplegia.
The results of CABG are affected by intraoperative techni-
cal factors, such as the quality of the coronary arteries and
conduits. That is not to say that intraoperative myocardial
protection is no longer important to the outcome of CABG.
Rather, a novel intervention concentrated during a short
period of cardioplegic arrest no longer has a meaningful
impact on clinical outcomes when one uses contemporary
methods of myocardial protection. However, perioperative
support with glucose-insulin-containing solutions may yet
prove useful when used both in the operating room and in
the intensive care unit. In addition, other high-risk sub-
groups, such as those with poor left ventricular function or
diabetic cardiomyopathy, may derive benefit from this form
of metabolic therapy. The results of several studies now in
progress should further define the role of metabolic en-
hancement during CABG.
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Appendix 1
Insulin Cardioplegia Trial (ICT) Investigators
Steering Committee: George T. Christakis, MD, Joan Ivanov, PhD,
C. David Naylor, MD, DPhil, Vivek Rao, MD, PhD, and Richard
D. Weisel, MD. Trial Coordinators: Michael A. Borger, MD,
Gideon Cohen, MD, PhD, Vania DeSouza, MD, and Barbara
Weller, RN. Safety, Monitoring, and Outcomes Committee: Davey
Cheng, MD, Jacek Karski, MD, Keyvan Karkouti, MD, C. David
Mazer, MD, Terry M. Smith, MD, Bill I. Wong, MD, and Terrence
M. Yau, MD. Biochemical Support: Frank Merante, PhD, Donald
A.G. Mickle, MD, Molly K. Mohabeer, and Laura C. Tumiati.
Participating Surgeons: Gopal Bhatnagar, MD, George T. Chris-
takis, MD, Stephen E. Fremes, MD, and Bernard S. Goldman, MD,
Sunnybrook and Women’s College Health Science Centre; and
Robert J. Cusimano, MD, Tirone E. David, MD, Christopher M.
Feindel, MD, Lynda L. Mickleborough, MD, Charles M. Peniston,
MD, Anthony C. Ralph-Edwards, MD, Hugh E. Scully, MD, Glen
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S. Van Arsdell, MD, Richard D. Weisel, MD, and Terrence M.
Yau, MD, Toronto General Hospital.
Appendix 2
Primary Study End Points
LOS has been previously defined by our group as the need for
intra-aortic balloon pump support or prolonged inotropic stimula-
tion (30 minutes after admission to the intensive care unit) after
operation. Patients requiring low-dose dopamine (5 g/[kg 
min]) for renal perfusion or those requiring vasopressors for low
systemic vascular resistance in the setting of high cardiac outputs
were not considered to have LOS. A clinical database manager
prospectively recorded the prevalence of LOS among all cardiac
surgical patients at each institution according to these objective
criteria. In the Insulin Cardioplegia Trial, the records of all patients
who received intra-aortic balloon pump or postoperative inotropic
support were flagged and reviewed by an independent outcomes
committee blinded to treatment group. Each record was reviewed
by a minimum of three individuals (see Appendix 1 for outcomes
committee members), and a determination of LOS was made by
majority opinion.
Enzymatic MI was determined from serial measurements of
CKMB. Measurements of CKMB were performed at 0, 2, 4, 8, 24,
and 48 hours after arrival at the intensive care unit. Integration of
the CKMB release over time curve was performed in all patients
with at least 4 samples (n  962, 85%). We previously reported
that integrated time values of 645 IU h are correlated with MI, as
assessed by technetium Tc 99m pyrophosphate imaging. An inte-
grated value greater than 1000 IU  h was used as a binary cutoff
for the determination of enzymatic MI. To account for survivors
with fewer than 4 samples, an analysis was repeated with two
different end points for enzymatic MI: peak CKMB greater than 20
and peak CKMB/creatine kinase ratio greater than 5%.
Discussion
Dr Edward D. Verrier (Seattle, Wash). How do you reconcile
the differences in all the experimental literature that show en-
hanced protection with the lack of efficacy in this clinical trial?
Dr Rao. That is a good question. I think that all the experi-
mental literature and even our previous studies in low-risk patients,
where we looked for very subtle differences, have demonstrated
benefit. The purpose of this trial was to see whether the subtle
differences that are obtained under highly controlled circum-
stances would translate into objective clinical benefit in the usual
population undergoing high-risk CABG. This study failed to dem-
onstrate that these improvements translated into meaningful clin-
ical benefit for these patients.
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